Trometamol 7.2% solution for infusion 5ml ampoules
Requires a prescription from a doctor or prescriber
An organic amine proton acceptor.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Trometamol
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Trometamol
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 13 · Randomised trials: 18 · 1990–2026
Showing the 50 most relevant studies, sorted by most relevant.
Florian Wagenlehner, Dimitri Abramov-Sommariva, Martina Höller, et al.
Urologia Internationalis, 2018
- Anti-Infective Agents
- Anti-Bacterial Agents
- Europe
Tommaso Cai, Andrea Novelli, Carlo Tascini, et al.
International Journal of Antimicrobial Agents, 2023
- Anti-Infective Agents
- Fosfomycin
- Anti-Bacterial Agents
Bhattarai BP, Selvido DI, Rokaya D
2024
Tommaso Cai, Irene Tamanini, Carlo Tascini, et al.
The Journal of Urology, 2019
- Acute Disease
- Anti-Bacterial Agents
- Fosfomycin
Vicente Esparza‐Villalpando, Amaury Pozos‐Guillén, David Masuoka‐Ito, et al.
Drug Development Research, 2017
- Analgesics
- Anti-Inflammatory Agents, Non-Steroidal
- Ketoprofen
Daniel Melecchi Freitas, Daniel M. Moreira
Arab Journal of Urology, 2019
M. Alfaresi, K. Hassan, Rafi Alnjadat
The Open Microbiology Journal, 2019
Jesús Sojo-Dorado, I. López-Hernández, A. Hernández-Torres, et al.
The Journal of antimicrobial chemotherapy, 2023
- Escherichia coli Infections
- Urinary Tract Infections
- Fosfomycin
Mahmut Erkal, C. Eroğlu
Head & Face Medicine, 2025
- Molar, Third
- Tooth, Impacted
- Tromethamine
Angkanavisan K, Sakboonyarat B, Ungthammakhun C
2026
ObjectivesTo determine whether oral fosfomycin trometamol is noninferior to carbapenem continuation as step-down therapy for cUTIs caused by third-generation cephalosporin-resistant Enterobacterales.MethodsIn this open-label, randomized, noninferiority trial, adults with 3GCRE cUTIs who received 3 days of intravenous carbapenem were assigned to oral fosfomycin trometamol or continued carbapenem to complete 7 days. The primary outcome was day-7 clinical cure; secondary outcomes included day-28 clinical and microbiological cure, readmission, and length of stay.ResultsA total of 124 participants were enrolled (62 per group). The mean age was 73 years, 62.1% were female, and Escherichia coli accounted for 91% of isolates. Clinical cure at day 7 occurred in 98.4% in both groups (risk difference 0.0; 95% CI -0.04 to 0.04). Clinical cure at day 28 was also similar (91.9% in each group). Microbiological cure at day 7 was 100% with fosfomycin and 98.1% with carbapenem, and at day 28 was 90.3% and 85.5%, respectively. Hospital stay was shorter with fosfomycin (7.9 vs 12.0 days).ConclusionsOral fosfomycin trometamol as step-down therapy was comparable to continued carbapenem therapy for cUTIs caused by 3GCRE and significantly reduced hospital stay, supporting role of carbapenem-sparing option.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medications. Always consult a healthcare professional.
Showing 1 of 1 interactions
Proteins and enzymes this drug interacts with in the body
PMID:25122912
Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb.
Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1 (By similarity).
By acting as a kinesin I membrane receptor, plays a role in axonal anterograde transport of cargo towards synapses in axons .
PMID:17062754 PMID:23011729
Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV.
The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1
ATC B05XX02
ATC B05BB03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Tromethamine
Matched from: Trometamol
Additional database identifiers
Drugs Product Database (DPD)
13337
ChemSpider
6257
PDB
TRS
ZINC
ZINC000000896695
HUGO Gene Nomenclature Committee (HGNC)
HGNC:457
GenAtlas
AMD1
GeneCards
AMD1
GenBank Gene Database
M21154
GenBank Protein Database
178518
UniProt Accession
DCAM_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:620
GenAtlas
APP
GeneCards
APP
GenBank Gene Database
X06989
UniProt Accession
A4_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q413961), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.